还原型谷胱甘肽治疗全身炎症反应综合征研究

Clinical Study of the Therapeutic Value of the Reduced Glutathione in Systemic Inflammatory Response Syndrome(SIRS)

目的研究还原型谷胱甘肽(GSH)对治疗全身炎症反应综合征(SIRS)的临床疗效以及对炎性介质的影响,了解GSH对SIRS的治疗价值。方法选择符合SIRS诊断标准的48例患者,随机分为GSH治疗组(A组)和常规治疗组(B组)。观察两组患者的临床效果并检测治疗前后血清IL-6、TNF-α、C-反应蛋白(CRP)、IL-10水平变化。结果治疗后A组患者临床症状改善较B组明显,MODS发生率下降,炎性介质CRP、IL-6、TNF-α、IL-10水平A组改变较B组明显改善。结论还原型谷胱甘肽能改善SIRS的临床症状,对炎性介质起免疫调理作用。

Objective To observe the therapeutic value of the reduced glutathione in critical illness cases with SIRS. Methods 48 SIRS patients were randomly divided into regular treatment group （ group B ） and reduced glutathione treatment group（group A）. The efficacy of the therapy in both the groups were assessed and serum levels of C RP,TNF-α,IL-6 and IL-10 were measured on admission and the fifth day. Results SIRS markers all reduced more significantly in group A than in group B （P〈0.01 ）. Serum CRP, TNF-α and IL-6 levels reduced more significantly in group A than in group B （P 〈 0. 01 ）. Conclusion Reduced glutathione significantly improved the clinical effects of SIRS, prevented the MODS incidence.